A Phase 1 Pharmacokinetic Study To Compare the Relative Bioavailability of Two Clinical Formulations of Linifanib in Subjects With Solid Tumors
This study is designed to evaluate the bioavailability of linifanib from 2 formulations.
Subjects may enroll in a separate extension study to continue receiving linifanib after
completion of this study.
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
To determine the pharmacokinetic profile of linifanib in subjects with advanced or metastatic solid tumors.
Blood samples for the pharmacokinetics (PK) of linifanib will be collected at designated time points and assayed.
At various time points from Day 1 through Day 5 of Periods 1 and 2
Mark D. McKee, MD
United States: Food and Drug Administration
|Site Reference ID/Investigator# 51403||Tacoma, Washington 98405|